Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH, Im SA, Park K, Wen J, Lee KH, Choi YL, Lee WC, Min A, Bonato V, Park S, Ram S, Lee DW, Kim JY, Lee SK, Lee WW, Lee J, Kim M, Kim HS, Weinrich SL, Ryu HS, Kim TY, Dann S, Kim YJ, Fernandez DR, Koh J, Wang S, Park SY, Deng S, Powell E, Ravi RK, Bienkowska J, Rejto PA, Park WY, Kan Z. Park YH, et al. Among authors: park s, park sy, park k, park wy. Genome Med. 2023 Jul 20;15(1):55. doi: 10.1186/s13073-023-01201-7. Genome Med. 2023. PMID: 37475004 Free PMC article.
Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, Choi YL, Park WY, Lee HM, Seol HJ, Shim YM, Joo KM, Nam DH. Lee HW, et al. Among authors: park wy. Clin Cancer Res. 2015 Mar 1;21(5):1172-82. doi: 10.1158/1078-0432.CCR-14-1589. Epub 2014 Dec 30. Clin Cancer Res. 2015. PMID: 25549722
Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, Yi JH, Hong M, Ahn T, Rath O, Schueler J, Kim ST, Do IG, Lee S, Park SH, Ji YI, Kim D, Park JO, Park YS, Kang WK, Kim KM, Park WY, Lim HY, Lee J. Lee JY, et al. Among authors: park c, park ys, park sh, park jo, park k, park wy. Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Oncotarget. 2015. PMID: 26296973 Free PMC article.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
Kim ST, Lee J, Hong M, Park K, Park JO, Ahn T, Park SH, Park YS, Lim HY, Sun JM, Ahn JS, Ahn MJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Uhm SW, Lee H, Min BH, Hong SN, Kim DH, Jung SH, Park W, Kim KM, Kang WK, Park K. Kim ST, et al. Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. Oncotarget. 2015. PMID: 26396172 Free PMC article. Clinical Trial.
HER2 as a novel therapeutic target for cervical cancer.
Oh DY, Kim S, Choi YL, Cho YJ, Oh E, Choi JJ, Jung K, Song JY, Ahn SE, Kim BG, Bae DS, Park WY, Lee JW, Song S. Oh DY, et al. Among authors: park wy. Oncotarget. 2015 Nov 3;6(34):36219-30. doi: 10.18632/oncotarget.5283. Oncotarget. 2015. PMID: 26435481 Free PMC article.
679 results